Published online before print January 10, 2008, doi: 10.1161/STROKEAHA.107.512244
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Stroke. 2008;39:250.)
© 2008 American Heart Association, Inc.
Advances in Stroke 2007 |
Introduction
From the University of Massachusetts Medical School, Worcester, Mass.
Correspondence to Marc Fisher, MD, UMASS/Memorial Health Care, 119 Belmont Street, Worcester, Mass, 01605-2982. E-mail fisherm@ummhc.org
Key Words: advances • stroke
An extract of the first 250 words of the full text is provided, because this article has no abstract. |
The annual update of a broad range of topics related to cerebrovascular diseases encompassed by the designated sections of Stroke is a widely appreciated feature. The current update was expanded from previous years to now include the new section of Population Studies, and additionally the basic science editors invited 2 updates with relevance to both basic scientists and clinicians. The editors hope that the readership will continue to value these brief but insightful updates and provide feedback as to how to potentially improve the material encompassed in the annual Advances section. We thank the section editors and the basic science contributors for their efforts.
In the genetics area, many important studies appeared using genome-wide associations with a variety of complex medical disorders. However, such a study of ischemic stroke did not demonstrate that a single locus of main effect could be determined. Genetic associations of single nucleotide polymorphisms are also becoming increasingly common. We can anticipate further studies of both types in helping to elucidate genetic contributions to a variety of cerebrovascular disorders.
Acute stroke therapies had another disappointing year with failure of the neuroprotective drug NXY-059 in a second, large phase III trial reported initially in late 2006 and in more detail subsequently. Additionally, the novel thrombolytic agent, desmoteplase, that had initially shown promise in 2 very small early phase II trials did not demonstrate benefit in a larger study presented at the 2007 European Stroke Conference. The reasons for this failure remain obscure and may be clarified after
This article has been cited by other articles:
 |
|
 |
|
  B. A. Gross, B. R. Bendok, Z. A. Hage, I. A. Awad, and H. H. Batjer Advances in Open Neurovascular Surgery 2007 Stroke, January 1, 2009; 40(1): 324 - 326. [Full Text] [PDF]
|
|